Literature DB >> 2121836

Levels of rifampin and ciprofloxacin in nasal secretions: correlation with MIC90 and eradication of nasopharyngeal carriage of bacteria.

R Darouiche1, B Perkins, D Musher, R Hamill, S Tsai.   

Abstract

To predict the efficacy of antibiotics in eliminating nasopharyngeal carriage of organisms such as Neisseria meningitidis, Haemophilus influenzae, and methicillin-resistant Staphylococcus aureus (MRSA), a novel approach for measuring drug concentrations in nasal secretions was developed. Five healthy individuals received four doses of rifampin and then, at a later date, ciprofloxacin. At 2, 5, and 8 h after the last dose, serum, saliva, and cold-stimulated nasal secretion samples were collected, and drug levels were analyzed by high-performance liquid chromatography. Nasopharyngeal levels of rifampin reached but did not substantially exceed 90% of the minimal inhibitory concentration (MIC90) for H. influenzae, exceeded the MIC90 for N. meningitidis, and were well above that for MRSA. Ciprofloxacin levels in nasal secretions far exceeded the MIC90 for meningococci and Haemophilus organisms but were below that for MRSA. These findings are consistent with the clinical studies showing that rifampin eliminates, in most instances, the nasal carriage of N. meningitidis and to a lesser extent H. influenzae. A single dose of ciprofloxacin has been shown to eradicate meningococci, yet a long course of treatment with this drug is not adequate for MRSA. On the basis of these results, clinical trials with ciprofloxacin to eliminate nasopharyngeal carriage of H. influenzae appear to be warranted.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2121836     DOI: 10.1093/infdis/162.5.1124

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  7 in total

1.  In vitro activities of streptomycin and 11 oral antimicrobial agents against clinical isolates of Klebsiella rhinoscleromatis.

Authors:  B A Perkins; R J Hamill; D M Musher; C O'Hara
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

2.  Pharmacokinetics of MHAA4549A, an Anti-Influenza A Monoclonal Antibody, in Healthy Subjects Challenged with Influenza A Virus in a Phase IIa Randomized Trial.

Authors:  Rong Deng; Ai Ping Lee; Mauricio Maia; Jeremy J Lim; Tracy Burgess; Priscilla Horn; Michael A Derby; Elizabeth Newton; Jorge A Tavel; William D Hanley
Journal:  Clin Pharmacokinet       Date:  2018-03       Impact factor: 6.447

3.  Independent behavior of commensal flora for carriage of fluoroquinolone-resistant bacteria in patients at admission.

Authors:  Victoire de Lastours; Françoise Chau; Florence Tubach; Blandine Pasquet; Etienne Ruppé; Bruno Fantin
Journal:  Antimicrob Agents Chemother       Date:  2010-09-27       Impact factor: 5.191

4.  Ciprofloxacin dosage and emergence of resistance in human commensal bacteria.

Authors:  Bruno Fantin; Xavier Duval; Laurent Massias; Loubna Alavoine; Françoise Chau; Sylvie Retout; Antoine Andremont; France Mentré
Journal:  J Infect Dis       Date:  2009-08-01       Impact factor: 5.226

Review 5.  A Qualitative Review on the Pharmacokinetics of Antibiotics in Saliva: Implications on Clinical Pharmacokinetic Monitoring in Humans.

Authors:  Tony K L Kiang; Mary H H Ensom
Journal:  Clin Pharmacokinet       Date:  2016-03       Impact factor: 6.447

6.  Decreased levofloxacin susceptibility in Haemophilus influenzae in children, Hong Kong.

Authors:  Pak-Leung Ho; Kin Hung Chow; Gannon C Mak; Kenneth W Tsang; Yu Lung Lau; Alex Y Ho; Eileen L Lai; Susan S Chiu
Journal:  Emerg Infect Dis       Date:  2004-11       Impact factor: 6.883

7.  Comparison of Drug Concentrations in Human Aqueous Humor after the Administration of 0.3% Gatifloxacin Ophthalmic Gel, 0.3% Gatifloxacin and 0.5% Levofloxacin Ophthalmic Solutions.

Authors:  Wenting Ding; Weiling Ni; Huilian Chen; Jingqun Yuan; Xiaodan Huang; Zheng Zhang; Yao Wang; Yibo Yu; Ke Yao
Journal:  Int J Med Sci       Date:  2015-06-10       Impact factor: 3.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.